Clinical trials consistently show substantial HbA1c reductions and 1015 percent or more weight loss, levels high enough to enable diabetes remission in selected earlystage patients, said Dr Joshi
In adults with overweight or obesity and metabolic dysfunctionassociated steatohepatitis, also known as MASH, with moderate or advanced fibrosis, the treatment plan should include a GLP-1RA or a dual GIP/GLP-1RA with demonstrated or potential benefits on MASH
Irregular sessions may delay visible glutathione IV results
Patients with a history of medullary thyroid carcinoma, MEN2, pancreatitis, or severe gastroparesis should seek specialist advice before use
While direct comparison is complicated by different trial designs and durations, the available data allows reasonable estimates